June 6, 2025, Basel, Switzerland –Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced the opening ceremony of the Chime Biologics European Innovation Hub and the establishment of the Chime Innovation Alliance were successfully held in Basel, Switzerland. The event attracted representatives from numerous pharmaceutical and biotechnology companies in Basel, Europe, and China, as well as partners of Chime Biologics, to jointly explore the future of the biopharmaceutical industry driven by the integration of European and Chinese innovations. As a core member of the Alliance, Qijun Jia , Founder and Chairman of Alioth, was invited to attend the event, joining industry leaders to explore new frontiers of China-Europe biomedical collaboration.

Alioth specializes in the development and application of filtration membrane-based solutions for pharmaceutical processes, offering a comprehensive portfolio spanning depth filtration, prefiltration, sterilizing-grade filtration, filtration hardware, and laboratory-scale filtration systems. Leveraging its end-to-end capabilities in membrane R&D and industrial-scale manufacturing, the company has successfully deployed its technologies in over 20 commercial-scale (2000L/10000L) and Phase III clinical drug manufacturing processes, with more than 100 applications across monoclonal antibodies, vaccines, recombinant proteins, blood products, cell & gene therapies (CGT), and small molecules.

As a participant in the Chime Innovation Alliance, Alioth will fully utilize its expertise in membrane technology innovation and filtration process optimization to deliver tailored solutions for clients at the European Innovation Hub, accelerating their drug development pipelines and commercial production timelines.

The establishment of the Chime Innovation Alliance marks not only a new engine for Sino-European biopharmaceutical collaboration but also a microcosm of the restructuring of the global innovation ecosystem. Alioth’s participation in the Alliance signifies a deepening of its internationalization strategy. Looking ahead, Alioth will continue to collaborate closely with Chime Biologics and Alliance partners through technology sharing and resource integration, jointly enhancing the collaborative efficiency of the global biopharmaceutical value chain and contributing to the accessibility and affordability of innovative medicines.